With no new cases reported for more than 100 days, Taiwan appears to have successfully contained the spread of COVID-19 and has drawn attention to its medical achievements. Experts said at BIO Asia-Taiwan conference this week that with continuous government and investor support, the East Asian nation could move further up to join other leading biotech players.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aptorum, Arcturus, Cel-Sci, Fujifilm, Hansoh, Menarini, Novavax, Protalix, Radius, Sarcomed, Sareum, Sorrento, Smartpharm, Tissue Regenix.
The support for permanent changes to Medicare coverage of telehealth has risen drastically in the months since the COVID-19 pandemic began, but Krista Drobac of Sirona Strategies said on a July 23 webinar that stakeholders will have to help make the case that telehealth is cost effective. That cost effectiveness argument may be absolutely crucial if any of the related legislative proposals are to stand up to budget scoring in a time of skyrocketing U.S. budget deficits, she said.
In the shadow of COVID-19, experts at the BIO Asia-Taiwan conference on Wednesday warned of present and future challenges for the biotech industry. Changes in manufacturing logistics and financial distress will continue to cause concern for the industry.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bionano Genomics, Codex DNA, Empirical Spine, Gs, Helixbind, Nuvasive, Oncocyte, Perfectprime, Personalis, Progenetics, Vectracor.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adial, Cymabay, Elsalys, Inotrem, Milestone, Neumentum, Vita.
RSS
